A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks

Trial Profile

A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Dyslipidaemias
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 17 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016 as per Clinical trials.gov record.
    • 17 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016 as per Clinical trials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top